Medical imaging company for the very early detection of Alzheimer's using biomarkers in the eye.

At $290B, Alzheimer’s is the most expensive disease in America. Drug failures in treating the disease have shifted the focus to pre-symptomatic Alzheimer’s and intervening earlier, before cognitive decline. Cognitively “healthy” individuals do not get tested for biomarkers, thus are hard to locate.

RetiSpec is the first accessible, non-invasive and scalable screening tool of Alzheimer’s disease biomarkers. RetiSpec detects Alzheimer’s biomarkers prior to symptoms, with a simple test as part of a routine eye exam.

Invested in

2019

Base

Toronto, ON

Sector

MedTech

CEO

Eliav Shaked